GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Cyclically Adjusted Price-to-FCF

PLx Pharma (FRA:1D5A) Cyclically Adjusted Price-to-FCF : (As of May. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


PLx Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for PLx Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Cyclically Adjusted Price-to-FCF Chart

PLx Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PLx Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PLx Pharma's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PLx Pharma's Cyclically Adjusted Price-to-FCF falls into.



PLx Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

PLx Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, PLx Pharma's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2022 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.394/125.2265*125.2265
=-0.394

Current CPI (Sep. 2022) = 125.2265.

PLx Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 0.000 96.871 0.000
201303 -0.370 98.209 -0.472
201306 -0.318 98.518 -0.404
201309 -1.059 98.790 -1.342
201312 -0.616 98.326 -0.785
201403 -2.263 99.695 -2.843
201406 -2.361 100.560 -2.940
201409 -2.001 100.428 -2.495
201412 -2.166 99.070 -2.738
201503 -2.629 99.621 -3.305
201506 -2.650 100.684 -3.296
201509 -3.046 100.392 -3.800
201512 -2.828 99.792 -3.549
201603 -3.535 100.470 -4.406
201606 0.800 101.688 0.985
201609 -0.055 101.861 -0.068
201612 -0.087 101.863 -0.107
201703 -0.470 102.862 -0.572
201706 -0.552 103.349 -0.669
201709 -0.172 104.136 -0.207
201712 -0.583 104.011 -0.702
201803 -0.371 105.290 -0.441
201806 -0.244 106.317 -0.287
201809 -0.136 106.507 -0.160
201812 -0.230 105.998 -0.272
201903 -0.332 107.251 -0.388
201906 -0.262 108.070 -0.304
201909 -0.334 108.329 -0.386
201912 -0.370 108.420 -0.427
202003 -0.371 108.902 -0.427
202006 -0.274 108.767 -0.315
202009 -0.290 109.815 -0.331
202012 -0.182 109.897 -0.207
202103 -0.220 111.754 -0.247
202106 -0.192 114.631 -0.210
202109 -0.284 115.734 -0.307
202112 -0.429 117.630 -0.457
202203 -0.557 121.301 -0.575
202206 -0.618 125.017 -0.619
202209 -0.394 125.227 -0.394

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PLx Pharma  (FRA:1D5A) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


PLx Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma (FRA:1D5A) Business Description

Industry
Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines